

### **VEGF R1/Flt1**

Catalog # PVGS1513

### **Specification**

#### **VEGF R1/Flt1 - Product Information**

Primary Accession **Species** Human P17948

Sequence Ser27-lle328

### **Purity**

> 95% as analyzed by SDS-PAGE

### **Endotoxin Level**

< 0.2 EU/ µg of protein by gel clotting method

### **Biological Activity**

Measured by its ability to inhibit the VEGF dependent proliferation of HUVEC (human umbilical vein endothelial cells). The ED<sub>50</sub> for this effect is < 30.0 ng/ml in the presence of 2.5 ng/ml rhVEGF165 (Cat. No.: Z02689).

# **Expression System**

CHO

Formulation

Lyophilized after extensive dialysis against PBS.

#### Reconstitution

It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in  $ddH_2O$  or PBS up to 100  $\mu g/ml$ .

## Storage & Stability

Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles.

### **VEGF R1/Flt1 - Additional Information**

### **Gene ID 2321**

#### **Other Names**

Vascular endothelial growth factor receptor 1, VEGFR-1, 2.7.10.1, Fms-like tyrosine kinase 1, FLT-1, Tyrosine-protein kinase FRT, Tyrosine-protein kinase receptor FLT, FLT, Vascular permeability factor receptor, FLT1, FLT, FRT, VEGFR1

### **Target Background**

Vascular endothelial growth factor receptor 1 (VEGF R1), also known as FMS-like tyrosine kinase



Tel: 858.875.1900 Fax: 858.875.1999

(Flt1), is a receptor tyrosine kinase which plays a critical role in angiogenesis. Human VEGF R1 contains a signal peptide (aa 1-22), an extracellular domain (ECD aa 27-758) with seven Ig-like repeats, a trans-membrane domain (aa 759-780) and a cytoplasmic region (aa 781-1338) with a tyrosine kinase domain and several autocatalytic phosphotyrosine sites. VEGFR-1 and VEGFR-2 are closely related receptor tyrosine kinases and have both common and specific ligands. VEGFR-1 is a kinase-impaired RTK whereas VEGFR-2 is a highly active kinase. Vascular endothelial growth factors (VEGFs) are crucial regulators of vascular development during embryogenesis (vasculogenesis) as well as blood-vessel formation (angiogenesis) in the adult. In mammals, five VEGF ligands, which occur in several different splice variants and processed forms, have been identified so far. These ligands bind in an overlapping pattern to VEGF receptor-1, -2 and -3 (VEGFR1-3), as well as to co-receptors (here defined as VEGF-binding molecules that lack established VEGF-induced catalytic function), such as heparin sulphate proteoglycans (HSPGs) and neuropilins.

#### **VEGF R1/Flt1 - Protein Information**

Name FLT1

Synonyms FLT, FRT, VEGFR1

#### **Function**

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. Acts as a positive regulator of postnatal retinal hyaloid vessel regression (By similarity). May play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation of endothelial cells. Can promote endothelial cell proliferation, survival and angiogenesis in adulthood. Its function in promoting cell proliferation seems to be cell-type specific. Promotes PGF-mediated proliferation of endothelial cells, proliferation of some types of cancer cells, but does not promote proliferation of normal fibroblasts (in vitro). Has very high affinity for VEGFA and relatively low protein kinase activity; may function as a negative regulator of VEGFA signaling by limiting the amount of free VEGFA and preventing its binding to KDR. Modulates KDR signaling by forming heterodimers with KDR. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leading to activation of phosphatidylinositol kinase and the downstream signaling pathway. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Phosphorylates SRC and YES1, and may also phosphorylate CBL. Promotes phosphorylation of AKT1 at 'Ser-473'. Promotes phosphorylation of PTK2/FAK1 (PubMed: <a href="http://www.uniprot.org/citations/16685275" target="blank">16685275</a>).

### **Cellular Location**

[Isoform 1]: Cell membrane; Single-pass type I membrane protein. Endosome. Note=Autophosphorylation promotes ubiquitination and endocytosis [Isoform 3]: Secreted. [Isoform 5]: Cytoplasm. [Isoform 7]: Cytoplasm.

### **Tissue Location**

Detected in normal lung, but also in placenta, liver, kidney, heart and brain tissues. Specifically expressed in most of the vascular endothelial cells, and also expressed in peripheral blood monocytes. Isoform 2 is strongly expressed in placenta. Isoform 3 is expressed in corneal epithelial cells (at protein level). Isoform 3 is expressed in vascular smooth muscle cells (VSMC)

### **VEGF R1/Flt1 - Protocols**





Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- <u>Immunohistochemistry</u>
- <u>Immunofluorescence</u>
- <u>Immunoprecipitation</u>
- Flow Cytomety
- Cell Culture

**VEGF R1/Flt1 - Images**